Introduction
Chronic lymphocytic leukemia (CLL) is a common, low grade malignancy of CD5 expressing B cells that may be either pre-or post-germinal centre 1, 2 . The condition is unusual among leukemias since it is frequently associated with immunologically mediated complications, which contribute substantially to morbidity and mortality. In particular, autoantibodies specific for red blood cells (RBC) are detectable by direct antiglobulin test (DAT) in up to 20% of advanced CLL cases and can cause autoimmune hemolytic anemia (AIHA) 3, 4 . Other common immunological complications include pure red cell aplasia and immune thrombocytopenic purpura [5] [6] [7] . In addition, rare autoantibodies can develop against factor VIII, von Willebrand factor, and C1 esterase inhibitor [8] [9] [10] . A striking feature of autoimmunity in CLL
is that it appears to be directed against constituents of the blood with no documented propensity to other targets 11 . However, despite the importance of this immune dysregulation in CLL, the causes of autoantibody production remain unclear.
Studies of animal models and human AIHA demonstrate that the activation of autoreactive helper T (Th) cells by antigen presenting cells (APC) is a key event in the induction of disease [12] [13] [14] [15] [16] [17] [18] [19] [20] . The generation of most IgG antibodies is T-cell dependent, and responses to RBC autoantigens appear to be no exception. Thus, in mice, T-cell depletion blocks the autoantibody response induced by cross-reactive rat RBC 12 . Furthermore, spontaneous anti-RBC autoantibody production in NZB mice can be retarded by anti-CD4 monoclonal antibody 14 or CD4 gene deletion 18 , and anemia can be modulated by peptides containing the dominant Th cell epitope 19 . We have previously demonstrated that patients with primary warm type AIHA mediated by IgG autoantibodies harbor activated Th cells specific for the Rh proteins 16, 17 , the dominant human RBC autoantigens 13, 20 , but there have been no studies of RBC-reactive Th cells in AIHA secondary to CLL. If AIHA associated with CLL is Th dependent, the question arises as to why the autoreactive Th cells are activated.
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In autoimmune disease, the B cell is largely studied in the context of pathogenic autoantibody production, whilst other functions, including antigen presentation, have often been ignored 21 . The RBC-and platelet-reactive autoantibodies identified in CLL patients are polyclonal and differ in specificity and isotype from the immunoglobulins secreted directly by CLL cells 22 . It is, therefore, generally accepted that residual, non-malignant B cells must produce the pathogenic autoantibodies in most cases [22] [23] [24] . We wished to test the hypothesis 24 that the malignant B cell may, instead, play an important role in presentation of autoantigen to activate pathogenic Th cells.
In a conventional immune response, B cells can act as "professional" APC, with the ability both to process and present antigen, and to express the co-stimulatory molecules necessary to stimulate Th cells 25, 26 . In murine models of autoimmune diseases, such as diabetes 27 and multiple sclerosis . Self-tolerance is maintained in part by the elimination or silencing of autoreactive lymphocytes 32, 33 , but Th cells specific for many autoantigens, including Rh proteins 34 , can escape these censoring mechanisms in healthy individuals.
There has been considerable interest in the hypothesis that such surviving autoreactive T cells can be activated and cause autoimmune disease following changes in APC function or type that enhance presentation of the epitopes they recognize 16, 17, 34, 35 .
As already mentioned, it is striking that autoimmunity in CLL predominantly targets blood constituents. We hypothesize that the large numbers of malignant B cells present in CLL can act as an aberrant APC population: when exposed to high concentrations of RBC and platelet breakdown products, there may be sufficient presentation of blood cell autoantigens 
Methods

Patients
AIHA was diagnosed in patients with CLL attending the Aberdeen Royal Infirmary on the basis of clinical and hematological investigation, and a positive DAT. The protocol for investigation was approved by the Grampian Health Board and the University of Aberdeen Joint Ethical Committee, and all patients gave informed consent. Details of the cases are summarized in Table 1A . Most blood samples were obtained when patients were receiving low to moderate doses of steroid treatment. A group of patients with CLL, but no evidence of clinical hemolysis, was also included (Table 1B) .
Determination of Autoantibody Specificity
Autoantibody eluted by ether treatment 13 from the RBC of AIHA patients, or serum antibody, was screened in hemagglutination assays for the ability to bind a panel of RBC consisting of
, r'r, r''r and rr cells.
Autoantibody samples were considered to include Rh specificities if they failed to react, or reacted very weakly, with Rh null cells, but strongly agglutinated other RBC phenotypes tested 13, 16 . Autoantibodies with Rh specificities were detected in all AIHA patients tested (Table 1) . 16, 17, 42 , the peptides were used to stimulate cultures at 20µg/ml.
As previously described was added to cultures at 20µg/ml. PPD readily provokes recall T cell responses in vitro, 16, 41 since most UK citizens have been immunized with Bacillus Calmette-Guérin (BCG).
Isolation peripheral blood mononuclear cells and preparation of T cells
As described elsewhere 16, 17, 42 , peripheral blood mononuclear cells (PBMC) were separated from fresh blood samples by density gradient centrifugation. T-cells were positively selected from PBMC using kits of magnetic beads coated with anti-CD2 monoclonal antibody, released and washed according to the manufacturer's instructions (CELLection, Dynal Biotech, Wirral, UK). Unbound PBMC were removed following magnetic separation and used as a source of APC.
Preparation of APC fractions by negative selection
Three APC fractions were prepared from T-depleted PBMC by successive negative selection steps using antibody-coated magnetic beads (Dynabeads, Dynal 
Positive selection of CLL B cells
In some experiments CLL B cells were isolated from the other potential APC types in Tdepleted PBMC by a single positive isolation step. Kits of magnetic beads (Dynal) coated with mouse anti-human CD5 (Pharmingen) were used, and the CD5 + cells released, according to the manufacturer's instructions (Dynal).
Flow cytometry
The purity of negatively and positively selected PBMC populations was screened by flow cytometry using an EPICS XL cytometer (Beckman Coulter) and Expo v2 analysis software 
Cell culture
Cell culture conditions have previously been described 16, 17, 42 . Briefly, PBMC were cultured at a concentration of 1.25 x 10 6 cells/ml in the alpha modification of Eagles medium (Gibco, Paisley, UK) supplemented with 5% autologous serum, 4mM L-glutamine (Gibco), 100U/ml sodium benzylpenicillin G (Sigma), 100µg/ml streptomycin sulfate (Sigma), and 20mM HEPES pH7.2 (Sigma), in a humidified atmosphere of 5% CO 2 /95% air. Similar conditions were used for T cells cultures, with APC supplied by adding an equal concentration of one of the different APC fractions.
T cell stimulation assays
As described elsewhere 16, 17, 42 , PBMC or T cells plus APC were cultured with antigen, and T cell proliferation was estimated from the incorporation of 
Inhibition of MHC class II restricted responses
Blocking mAbs specific for HLA -DP, -DQ, or -DR supplied by Pharmingen were dialyzed thoroughly against PBS before addition to PBMC cultures at the previously determined optimum concentration of 2.5µg/ml 16, 42 .
RESULTS
T cell responses to the RhD protein and peptide panel
We have previously demonstrated that the blood of patients with primary AIHA contains activated Th cells specific for epitopes on the RhD and RhCcEe proteins 16, 17 . Experiments were set up to determine whether such Th cells are also present in AIHA secondary to CLL.
PBMC were obtained from twelve CLL patients with concurrent AIHA (details in Table 1 ) and tested for the ability to proliferate in response to Rh protein and/or the corresponding panel of peptides. Given the ethical constraints on the size of the blood samples, and thus the number of Th cells available, we were only able comprehensively to study responses against either the RhD or RhCcEe sequences in each case. It was important to ensure that the responses observed were autoimmune and therefore that the Rh sequences tested corresponded to "self". Most of the patients were D-positive, and, for these individuals, we focused on the RhD rather than the RhCcEe polypeptide. This enabled us to take advantage of our validated method for immunopurifying RhD protein from RBC 17 , allowing a comparison with previous data of Th cell responses in primary AIHA patients 16, 17 , and obviated the need to match the type of the polymorphic RhCcEe protein sequence with each patient.
Representative results from three of the ten RhD-positive patients, who were screened with purified RhD protein and the RhD peptide panel, are illustrated in Figure 1 and data from all patients are summarized in Table 2A . In all the RhD-positive patients, purified RhD protein induced proliferative responses by PBMC. Furthermore, it can be seen that one or more peptides from the RhD protein elicited significant proliferation by PBMC from all patients tested, and, typically, multiple peptides were stimulatory. Comparable results were obtained in the two RhD-negative patients, whose PBMC proliferated in response to multiple peptides from the sequence of the Rhce protein autoantigen. As in our previous studies of primary AIHA 16, 17 , proliferation was assessed on day five after stimulation, and cell culture was Examples of this lack of responsiveness in healthy donors are illustrated in Figure 2 . We now wished to ascertain whether there may be sub-clinical anti-RBC autoimmune responses in CLL patients with no overt signs of AIHA. It was determined whether the PBMC from ten such CLL patients were able to proliferate in response to Rh protein and/or Rh peptides, and the results are summarized in Table 2B , with representative data from three individuals illustrated in Figure 3 . PBMC from eight of ten patients proliferated when stimulated with purified RhD protein, and six of these eight individuals were also responsive to multiple peptides from the Rh sequence.
Antibody levels
One explanation for the responsiveness of PBMC from patients with CLL, but no overt AIHA, is that Th cells in these cases are providing help for anti-RBC autoantibodies that are undetectable by DAT and do not cause clinical hemolysis. Accordingly, a sensitive IELAT was used to compare the levels of RBC-reactive antibodies in the sera of healthy control donors, primary AIHA patients, the patients with AIHA secondary to CLL, and the patients with CLL but no clinical hemolysis. Figure 4 demonstrates that, as expected, high levels of antibody were present in the sera of most of the patients with either primary or secondary AIHA, but antibody levels were also elevated in six of the ten CLL patients without overt
AIHA. Importantly, all of these antibody-positive, but AIHA-negative, CLL patients showed proliferative responses to the RhD protein.
Comparison of responses to Rh protein epitopes in primary and CLL associated AIHA
The question arises as to how the fine specificities of the Rh-specific Th cells in cases of CLL with secondary AIHA compare with those previously identified in primary AIHA patients 16, 17 . 
Capacity of different APC types to stimulate Th cells responsive to Rh protein
Having shown that CLL is associated with responsiveness of Rh-reactive Th cells, we next To confirm that CLL B cells were able to present Rh protein effectively, T cells were stimulated with purified autoantigen in the presence of freshly isolated CD5 + cells that had been positively selected from T-depleted PBMC. The results are summarized in Table 3 
Capacity of different APC types to stimulate Th cells responsive to Rh peptides
There are at least two possible explanations for the ability of CLL B cells to present RhD autoantigen: the tumor cells may either take up and process the antigen more effectively than other APC types, or preferentially present to autoreactive T cells. To address this question, we determined whether the different APC fractions from four CLL patients could stimulate T cells specific for the respective dominant peptides that had been identified earlier.
The results are summarized in 
Discussion
We here describe a novel role for malignant B cells in the autoimmune pathology associated . Together, these data lead us to conclude that AIHA secondary to CLL is Th driven, and suggest that, as in primary AIHA, the breakdown of self-tolerance may be due to changes in autoantigen presentation 35 .
The results also demonstrate that anti-RBC autoimmune responses are more common in CLL patients than the incidence of overt AIHA would suggest. The view that latent autoimmunity is underestimated in CLL is supported by previous studies using a mitogen- . Whatever the reasons for the efficacy of CLL cells as APC for Rh protein, the uncontrolled expansion of these malignant cells in vivo, combined with their localization with blood breakdown products, provides the opportunity to activate autoreactive Th cells specific for RBC, platelet and other blood-derived antigens. It is yet to be determined where the Th cell activity occurs, but the spleen is likely to be important, given its role as a secondary lymphoid organ and a major site where blood cell 
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